New Delhi: As the Ebola outbreak linked to the Bundibugyo strain continues to spread across parts of Central Africa, India is strengthening its role in the global response by supporting the development of a new vaccine candidate while enhancing domestic surveillance and preparedness measures.
The current outbreak, centered in the Democratic Republic of Congo (DRC) and affecting neighboring Uganda, has raised international concern due to the absence of an approved vaccine or specific treatment for the Bundibugyo strain. Global health authorities have warned that the outbreak is expanding rapidly, with hundreds of confirmed cases and significant fatalities reported in the region.
In a major boost to vaccine development efforts, the Serum Institute of India (SII) is collaborating with the University of Oxford to manufacture clinical trial doses of an experimental Ebola vaccine. The initiative has received financial support from the Coalition for Epidemic Preparedness Innovations (CEPI), aiming to accelerate the development and testing of a vaccine specifically targeting the Bundibugyo virus.
Experts involved in the project have indicated that clinical-grade vaccine doses could be ready within the next few months, offering hope for a faster response if trials demonstrate safety and effectiveness. The vaccine is among several candidates being fast-tracked globally as researchers race to contain the outbreak.
Meanwhile, the Indian government has intensified surveillance measures across airports, ports, and healthcare facilities. The Union Health Ministry has conducted high-level review meetings and directed states and Union Territories to strengthen screening, laboratory preparedness, and rapid response mechanisms. Authorities have clarified that no confirmed Ebola case has been detected in India so far.
Public health experts note that while the immediate risk to India remains low, increased international travel and the evolving nature of the outbreak warrant continued vigilance. The World Health Organization (WHO) has declared the Ebola outbreak a Public Health Emergency of International Concern and emphasized the need for coordinated international action, including vaccine development, disease surveillance, contact tracing, and community engagement.
India’s growing contribution to vaccine research and manufacturing underscores its expanding role in global health security. As the world races to contain the outbreak, the success of emerging vaccine candidates could prove critical in preventing further spread of the deadly disease and protecting vulnerable populations.
